Multiple Myeloma

Unleashing Our Immune Response to Quash Cancer

February 21, 2024

New Multiple Myeloma Staging Systems Outperform the Standard

December 20, 2023

Multiple Myeloma

In real world, patients with myeloma have worse outcomes

December 11, 2023

Multiple Myeloma

FDA OKs new agent to block chemotherapy-induced neutropenia

November 29, 2023

FDA panel voices concerns over 2 lymphoma accelerated approvals

November 17, 2023

Frontline myeloma treatments: ASCT vs. CAR T

October 25, 2023

Multiple Myeloma

Debate: Should smoldering myeloma be treated?

September 14, 2023

Multiple Myeloma

FDA approves motixafortide for stem cell mobilization in myeloma

September 11, 2023

ClonoSEQ Testing for Minimal Residual Disease in Multiple Myeloma: Cleveland VA Experience And Cost Analysis

September 10, 2023

Comparing Outcomes and Toxicities With Standard and Reduced Dose Melphalan in Autologous Stem Cell Transplant Patients With Multiple Myeloma

September 10, 2023

FDA approves elranatamab for multiple myeloma

August 15, 2023

Multiple Myeloma

FDA OKs talquetamab, a first-in-class myeloma tx

August 10, 2023

Multiple Myeloma

Antibody shows promise in preventing GVHD

August 8, 2023

ESMO helps hematologists assess new cancer drugs

June 28, 2023

Multiprong strategy makes clinical trials less White

June 23, 2023